131 related articles for article (PubMed ID: 21095206)
1. Lung surfactant DPPG phospholipid inhibits vaccinia virus infection.
Perino J; Crouzier D; Spehner D; Debouzy JC; Garin D; Crance JM; Favier AL
Antiviral Res; 2011 Jan; 89(1):89-97. PubMed ID: 21095206
[TBL] [Abstract][Full Text] [Related]
2. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
3. ESR and NMR studies provide evidence that phosphatidyl glycerol specifically interacts with poxvirus membranes.
Debouzy JC; Crouzier D; Favier AL; Perino J
Virol J; 2010 Dec; 7():379. PubMed ID: 21194478
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia virus-induced smallpox postvaccinal encephalitis in case of blood-brain barrier damage.
Garcel A; Fauquette W; Dehouck MP; Crance JM; Favier AL
Vaccine; 2012 Feb; 30(7):1397-405. PubMed ID: 22227123
[TBL] [Abstract][Full Text] [Related]
5. Role of sulfatide in vaccinia virus infection.
Perino J; Foo CH; Spehner D; Cohen GH; Eisenberg RJ; Crance JM; Favier AL
Biol Cell; 2011 Jul; 103(7):319-31. PubMed ID: 21554243
[TBL] [Abstract][Full Text] [Related]
6. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
7. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.
Lustig S; Maik-Rachline G; Paran N; Melamed S; Israely T; Erez N; Orr N; Reuveny S; Ordentlich A; Laub O; Shafferman A; Velan B
Vaccine; 2009 Mar; 27(11):1691-9. PubMed ID: 19195492
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus.
Parkinson JE; Smith GL
Virology; 1994 Oct; 204(1):376-90. PubMed ID: 8091668
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine.
Garcel A; Perino J; Crance JM; Drillien R; Garin D; Favier AL
Vaccine; 2009 Jan; 27(5):708-17. PubMed ID: 19059294
[TBL] [Abstract][Full Text] [Related]
10. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Engelstad M; Smith GL
Virology; 1993 Jun; 194(2):627-37. PubMed ID: 8503178
[TBL] [Abstract][Full Text] [Related]
11. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
12. Measurements of vaccinia virus dissemination using whole body imaging: approaches for predicting of lethality in challenge models and testing of vaccines and antiviral treatments.
Zaitseva M; Kapnick S; Golding H
Methods Mol Biol; 2012; 890():161-76. PubMed ID: 22688767
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
14. Laboratory-acquired vaccinia exposures and infections--United States, 2005-2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(15):401-4. PubMed ID: 18418346
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model.
Phelps A; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2005 May; 23(27):3500-7. PubMed ID: 15855008
[TBL] [Abstract][Full Text] [Related]
16. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
Gurt I; Abdalrhman I; Katz E
Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
[TBL] [Abstract][Full Text] [Related]
18. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.
Rees DG; Gates AJ; Green M; Eastaugh L; Lukaszewski RA; Griffin KF; Krieg AM; Titball RW
Antiviral Res; 2005 Feb; 65(2):87-95. PubMed ID: 15708635
[TBL] [Abstract][Full Text] [Related]
19. A recombinant vaccinia virus encoding the interferon-inducible T-cell alpha chemoattractant is attenuated in vivo.
Hamilton NH; Mahalingam S; Banyer JL; Ramshaw IA; Thomson SA
Scand J Immunol; 2004 Mar; 59(3):246-54. PubMed ID: 15030574
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
